Background: Rituximab has been associated with hepatitis B virus reactivation (HBV-R). However, the characteristics and scope of this association remain largely undefined.
The anti-CD20 monoclonal antibody, rituximab, has revolutionalized the treatment of NHL. Rituximab is an overall well-tolerated drug with minimal late toxicity. However, recent data have suggested an increased risk of infectious complications, in particular viral mediated [15] . In July 2004, based on three case reports [16] [17] [18] , the Food and Drug Administration (FDA) and manufacturers of rituximab issued a 'Dear Health Care Professional' letter regarding rituximab-associated HBV-R and encouraged health care professionals to submit any related reports to the FDA Adverse Event Reporting System (AERS) MedWatch system [19] . Since that time, multiple case reports and several retrospective series of rituximab-induced HBV-R have been reported in the literature and submitted to the FDA. In addition, several recent reports have documented fatal 'late' HBV-R occurring >6 months after completion of rituximab [20] [21] [22] [23] [24] , which is an unusual occurrence with chemotherapy-associated HBV-R (i.e. without rituximab) [14] . Despite these reports, the characteristics and scope of rituximab-induced HBV-R remain poorly characterized. Moreover, the absolute risk that rituximab contributes to HBV-R in HBcAb(+) or HBsAg(+) patient populations is not known.
Through a systematic literature review, we examined the characteristics, incidence, and clinical outcomes of patients with lymphoproliferative diseases, who developed HBV-R after exposure to rituximab-based therapy. Further, we analyzed the quality and completeness of case reports available in the medical literature compared with those reported to the FDA. We also completed a meta-analysis in order to estimate the risk that rituximab adds to HBV-R.
methods data sources
The literature search covered the period from November 1997, the date rituximab received its initial FDA approval, through 30 September 2009 (Medline and EMBASE MeSH search terms: hepatitis, HBV, rituximab, monoclonal antibody, lymphoma, and lymphoproliferative diseases, including chronic lymphocytic leukemia (CLL). Data sources included two surveillance cases at Northwestern Memorial Hospital, two cases at Chang Gung Memorial Hospital in Taiwan, and 183 unique reports from the medical literature. The FDA AERS data was from the same time period (November 1997 through September 2009), using all Medical Dictionary for Drug Regulatory Affairs preferred terms that contained 'HBV' and was limited to patients whose documented indication for rituximab included lymphoproliferative diagnoses. We identified 118 unique cases in the FDA MedWatch database (104 of which submitted as 'expedited' reports).
study selection
Three independent reviewers extracted data from all case reports, case series, and cohort series that reported an association of rituximab with HBV-R. Inclusion criteria for rituximab-associated HBV-R included receipt of at least one dose of rituximab (alone or combined with other therapy) for the treatment of a lymphoproliferative disease before HBV-R and no history of prior solid organ transplant or hematopoietic stem cell transplantation. Duplicate reports were identified based on demographic and clinical criteria, including age, sex, concomitantly administered drugs, and underlying illnesses. Two literature reports of rituximab-associated HBV-R not associated with NHL were excluded (vasculitis [25] and gloumerulonephritis [26] ).
For literature reports, HBV-R was defined as a >10-fold rise in serum HBV DNA levels with an accompanying increase in serum ALT compared with baseline. HBV-related hepatitis was defined as an increase in serum ALT more than two times greater than baseline and a 10-fold increase in serum HBV DNA levels, while HBV-related liver failure was defined as elevated serum ALT level together with prolonged prothrombin time or other evidence of coagulopathy. HBV-related death was defined as death of a patient, who had documented HBV-R, evidence of fulminant liver failure, and no other apparent cause of death.
data analysis
The statistical signal strength of the association between rituximab exposure in lymphoproliferative patients and HBV-R was calculated using the proportional reporting ratio (PRR) and the Empirical Bayesian Geometric Mean (EBGM) [27] [28] [29] . The PRR and EBGM were calculated by identifying all patients in the FDA AERS from rituximab's initial FDA approval, who were treated for a lymphoproliferative disease. These signal detection calculations provide assessments of the disproportionality of the frequency of a specific reaction for a given drug in comparison to what would be predicted for that drug based on reports of that adverse effect associated with all other drugs in the dataset. A completeness analysis was carried out comparing completeness of cases submitted to the FDA AERS database compared with cases abstracted from the medical literature or from our active surveillance efforts; we prespecified the covariates to be collected prior to data abstraction. To compare frequencies, we used Fisher's exact test. The Wilcoxon rank sum test was utilized to analyze differences in patient ages and time to HBV-R. We used Thomas Lumley's Bioconductor package 'rmeta', version 2.16: to carry the calculations for the meta-analysis of the incidence of rituximab-associated HBV-R, to conduct the Mantel-Haenszel analysis [and confidence intervals (CIs)], to carry the Woolf test for heterogeneity, and to create the forest plots. In order to obtain forest plots for studies that contained a zero count, we added a single count to all cells in the corresponding 2 · 2 table.
results

patients' characteristics
From 1997 through 2009, 183 rituximab-associated HBV-R unique cases were reported in the medical literature: 27 published as case reports and 156 through case series. The vast majority (99%) of these cases were reported after 2004 with 85% reported in the last 2 years. The 2 Northwestern cases, 2 Taiwan surveillance cases and 27 literature case reports were grouped together for purposes of analysis. In this group of 31 patients, 16 had HBcAb(+) (HBsAg2) rituximab-associated HBV-R, while 15 had HBsAg(+) (Tables 1 and 2 ). The median age at HBV-R was 55 years, range 21-79 (19 males/12 females); median age for HBcAb(+) patients was 60.5 years, and 42 years for the HBsAg(+) group (P = 0.05). Lymphoproliferative histologies were diffuse large B-cell lymphoma (n = 19), indolent NHL (n = 8), CLL (n = 2), and mantle-cell lymphoma (n = 2). Of note, 25 of these 31 patients had received concurrent immunosuppressive therapy (chemotherapy 6 glucocorticosteroids n = 23, glucocorticosteroids alone n = 2), while only 6 cases involved single-agent rituximab treatment. Each of these six latter patients had received additional immunosuppressive therapy prior to rituximab treatment (at 2, 3, 4, 12, 24, and 34 months).
The median number of rituximab doses received before HBV-R was 6 (range 3-10). The median time from last rituximab dose to HBV-R was 3 months (range 0-12), while Comparison of completeness of source data of the literature case reports versus the FDA AERS reports is contained in Table 3 . The literature cases were more complete with an overall completeness ratio for literature reports versus the FDA cases of 2.37 (P < 0.0001).
case series: meta-analysis of HBV reactivation
Of rituximab-associated HBV-R cases reported through case series (n = 156), 80 were HBcAb(+)/HBsAg(2) and 76 HBsAg(+) ( Tables 4 and 5 ). Of all case series, five included a control group (i.e. treated with nonrituximab therapy) [46, 48, 49, 51, 53] ; the series by Wang et al. [54] was not included as HBV-R was not adequately defined. The cumulative incidence of rituximab-associated HBV-R among these five series was significantly higher at 8.2% (20 of 244) compared with 0.6% (3 of 453) for the chemotherapy-alone group (P < 0.0001). The pooled effect of rituximab-based therapy on HBV-R remained significantly increased under a fixed effects model [odds ratio (OR) 5.64, 95% CI 2.18-14.54, P = 0.0003] with no evidence of heterogeneity between studies (Figure 1 ). Since only one of the five series in the meta-analysis contained a HBsAg(+)-related series [53] , it is difficult to draw definitive conclusions among this patient group regarding the added risk that rituximab contributes to reactivation. If only the four HBcAb(+) case series are included in the meta-analysis [46, 48, 49, 51] , the OR remained highly significant at 5.73 (95% CI 2.01-16.33; Z = 3.33, P = 0.0009) without heterogeneity (v 2 = 2.12, P = 0.5473). It should also be noted, that the incidence and mortality rates of rituximab-associated HBV-R varied considerably across all case series. Among all HBcAb(+) case series, the incidence of HBV-R ranged from 2.7% to 45%, while the associated mortality rates varied from 0% to 50% (Table 4) . For HBsAg(+) cases, the rate of HBV-R ranged from 16% to 80% (Table 5) .
antiviral prophylaxis data
Among HBsAg(+) case series, data regarding the effectiveness of prophylactic antiviral medications in rituximab-treated patients was mixed. Tsutsumi et al. [53] showed that 0 of 10 rituximabtreated patients who received antiviral prophylaxis had HBV-R, while 4 of 15 (27%) without lamivudine prophylaxis experienced HBV-R. However, we recently reported that use of prophylactic lamivudine did not decrease the risk of HBV-R with a rate of reactivation of 80% among rituximab-based treated patients regardless of use of antiviral prophylaxis (Table 5 ) [55] . In our case series, we noted two episodes of breakthrough HBV-related hepatitis associated with lamivudine-resistant tyrosinemethionine-aspartate-aspartate HBV mutants.
discussion
Through a comprehensive literature review and meta-analysis, we attempted to characterize the scope of rituximab-associated HBV-R. The vast majority of rituximab-related clinical trials have excluded patients with history of HBV exposure; thus, the extent of rituximab-associated HBV-R data is primarily from the medical literature and through reports to the FDA MedWatch system. Over a 12-year period, 183 cases of rituximab-associated HBV-R were reported through the medical literature and 118 cases to the FDA. From literature case reports, 55% of patients experienced liver failure, while the associated mortality rate was 48%. In addition, from case series that had an associated nonrituximab-treated control group, a significant increase in rituximab-associated HBV-R was documented. In interpreting these observations, several factors should be considered. Increasing evidence has linked rituximab to viral infections including herpes simplex virus, cytomegalovirus, and JC virus [15, 56] . In February 2006, the rituximab label was changed to include information for NHL patients who developed serious viral infections after rituximab treatment [57] . However, the incidences and characteristics of these infections, including risk factors, remain to be elucidated. In addition, the pathophysiology of rituximab-induced viral infections is unclear. The mechanism underlying HBV-R following rituximab treatment is likely more complex than simple B-cell depletion. B-lymphocytes may stimulate cellular immune responses, both to auto-antigens and foreign antigens [58] . Further, Stasi et al. [59] demonstrated following rituximab treatment that significant changes occur in T-lymphocyte activity, including increased Th1/Th2 and Tc1/Tc2 ratios, increased expression of Fas ligand on Th1 and Th2 cells, and expansion of oligoclonal T cells. A role for the importance of Blymphocytes in HBV-R may also be in part related to reduction of anti-HBV antibodies (i.e. HBsAb+) caused by rituximab and the associated host immunity balance. Tsutsumi et al. [39] showed that despite serum immunoglobulin levels remaining constant through treatment, anti-HBV surface antibody titers significantly decreased with rituximab therapy.
In our data, we found that among HBcAb(+) cases series with an associated nonrituximab-treated control group, there was a more than fivefold higher rate of HBV-R for patients who received rituximab-based therapy. It should also be noted that only one HBV case series was prospective; in that study, Yeo et al. [49] found a HBV-R rate of 25% among HBcAb(+) lymphoma patients, who received rituximab-combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) compared with 0 for CHOP. Given the retrospective nature of most reports and the wide range of HBV-R (3%-45%), it is difficult to make firm recommendations for HBcAb(+) patients. However, in the United States and Europe, it is becoming standard practice to administer antiviral prophylaxis for this patient population [60] , although continued prospective studies are needed to clearly delineate the benefit of this strategy.
Controlled data regarding the risk of single-agent rituximab-induced HBV-R in HBsAg(+) or the added risk of rituximab to chemotherapy in this patient population are sparse. Only one of the available five HBsAg(+) case series included a control group treated without rituximab; in that study, Tsutsumi et al. [53] showed that 16% of patients treated with rituximab alone or rituximab/chemotherapy experienced HBV-R compared with 0 patients who received chemotherapy alone. In chemotherapy-related HBsAg(+) studies, the antiviral agent lamivudine has been associated with a significant reduction in chemotherapy-associated HBV-R-related mortality to <5% to 10% compared with 60% to 70% without prophylaxis [9, 11] . Tsutsumi et al. [53] found that 0 of 10 HBsAg(+) rituximab-treated patients given lamivudine had HBV-R compared with 4 of 15 rituximabtreated patients not given prophylaxis. However, we recently reported that prophylactic lamivudine did not decrease the risk of HBV-R in rituximab-treated HBsAg(+) patients, although total patient numbers were small (n = 15) [61] ; however, of the four of five HBsAb(+) patients treated with rituximab-based therapy without prophylaxis who experienced HBV reactivation, three of the four occurred after withdrawal of antiviral prophylaxis (duration of prophylaxis: median 2 months after last rituximab dose). An important consideration is the optimal length of antiviral prophylaxis. Several groups advocate continuation of antiviral therapy for at least 6 months following the last cycle of chemotherapy and longer after rituximab [62] . Although with extended use of antiviral therapy, lamivudine resistance is a growing area of concern (up to 30%-35%) [40, 42, 45, 63] . Newer, more potent antivirals with much lower rates of HBV resistance, such as adefovir and tenofovir, should be examined. It was interesting that over the same period where 183 unique cases were published in peer-reviewed medical literature, only 118 cases were reported to the FDA. Of note, all serious adverse events (such as HBV-R) that occur in United States, as well as ex-United States, are required to be reported to the FDA. FDA AERS is a passive surveillance system with associated limitations including underreporting, reporting bias, and data completeness. Indeed, we found that cases published in the medical literature were highly superior in data quality compared with FDA reports. Case reports in the FDA database need to be interpreted cautiously as not all cases are systemically validated. Furthermore, the FDA AERS data do not provide true incidence or prevalence information due to lack of information of number of patients exposed. This limits analyses to validated data mining signal detection techniques [27] [28] [29] . Nevertheless, it should be acknowledged that the FDA AERS system is worldwide in its scope for drugs approved in the United States and it often provides important safety signals.
Some limitations of our analysis should be noted. The number of HBV-R occurrences depicted here are likely an underestimation of the true incidence. It is difficult to accurately estimate the incidence of rituximab-associated HBV-R among persons with NHL in part due to incomplete reporting of reactivation cases among rituximab-treated patients and incomplete data on the number of unique patients with lymphoid malignancies who have received rituximab. On the other hand, HBV-R cases with morbid/fatal complications are more likely to be reported. Additionally, an interpretation has been that HBV-R occurs mostly in endemic HBV areas (e.g. Hong Kong and Taiwan) [55, 64, 65] . Rates are not as high, but recent data from urban USA centers show that 10% of all cancer patients treated with immunosuppressive therapy have past or active HBV infection [66, 67] . The retrospective nature of the majority of rituximab-associated HBV-R cases also makes definitive conclusions difficult regarding incidence and mortality. However, given the results of the meta-analysis and the fact that nearly one-third of HBV-R in case reports occurred >6 months after the last rituximab dose, which is an unusual occurrence with chemotherapy alone, supports the likelihood of a real effect of rituximab-mediated HBV-R. 'Delayed' HBV-R (i.e. >6 months) may in part be explained by the long half-life of rituximab, whereby serum levels (and B-cell suppression) may be detected in patients for >6 months [68] , while other factors may also be involved (e.g. immunoglobulins and T-cell immunity).
In conclusion, rituximab therapy may increase the risk of developing HBV-R and associated liver failure and death in HBcAb(+) and HBsAg(+) patient populations. As rituximab continues to gain more indications of use (including nonmalignant indications) and newer monoclonal CD20 antibodies become clinically available (e.g. ofatumumab), it is important that clinicians and patients be aware of the potential for HBV-R. In the absence of prospective data, it is advisable that patients with HBV infection [HBsAg(+) or HBcAb(+)], who receive rituximab-based therapy receive concomitant antiviral prophylaxis and for at least 9 months after the last rituximab dose. It is critical, however, that prospective studies of antibody-induced HBV-R continue as many unanswered questions remain (i.e. risk of HBV-R with single-agent rituximab; the ideal type, length, and benefit of antiviral prophylaxis, especially in HBsAg(+) populations; identification of additional risk factors (e.g. co-infection with hepatitis C, D, and/or E viruses [69, 70] ); and mechanisms of rituximabassociated HBV-R). Finally, increased efforts should be given toward post-marketing drug surveillance and the timely dissemination of data to practicing physicians. acknowledgements
